Reinventing
Biopharma

Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D.

About Roivant

We believe that the key to unlocking innovation in drug discovery and commercialization is reducing the time and cost of the drug development process.

We do this by building Vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. Since 2014, Roivant has scaled its production of new Vants, with 14 fully built to date and additional Vants under construction.

We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. We also launch new healthcare technology companies to improve the process of developing and delivering all new medicines to patients.

 

Founder and CEO Vivek Ramaswamy Presents at Roivant Pipeline Day

OUR VANTS

Myovant

Dedicated to women’s health and prostate cancer.

OUR VANTS

Enzyvant

Developing transformative therapies for patients with rare diseases.

OUR VANTS

Axovant

Finding new solutions in neurology.

OUR VANTS

Metavant

Looking beyond the current options for cardiometabolic disorders.

OUR VANTS

Urovant

Improving quality of life through advancements in urology.

OUR VANTS

Dermavant

Leading innovation in medical dermatology.

OUR VANTS

Sinovant

Bringing medical innovation to China.

OUR VANTS

Genevant

Delivering results through RNA therapeutics.

OUR VANTS

Altavant

Elevating patient-centric drug development.

OUR VANTS

Arbutus

Working towards a cure for hepatitis B.

OUR VANTS

Respivant

Serving patients suffering from respiratory diseases.

OUR VANTS

Immunovant

Breaking barriers in immunology to restore patient health.

OUR VANTS

Aruvant

Developing gene therapies for hematological conditions.

OUR VANTS

Datavant

Organizing the world's healthcare data.

OUR WORK

Pipeline

We have a diverse pipeline of over 35 investigational drugs in 14 therapeutic areas across our family of companies.

COMPANY
COMPOUND
INDICATION
PHASE
Company Compound Indication PRECLIN Phase 1 Phase 2 Phase 3
MYOVANT RELUGOLIX

Uterine Fibroids

3

Endometriosis

3

Prostate Cancer

3

MVT-602

Female Infertility

2

ENZYVANT RVT-801

Farber Disease

Preclin

RVT-802

Complete DiGeorge Anomaly

3

AXOVANT AXO-LENTI-PD

Parkinson's Disease

1

AXO-AAV-OPMD

Oculopharyngeal Muscular Dystrophy

Preclin

METAVANT IMEGLIMIN

Diabetes

2

RVT-1502

Diabetes

2

UROVANT VIBEGRON

Overactive Bladder

3

Overactive Bladder in Men with BPH

2

IBS-Associated Pain

1

hMaxi-K

Overactive Bladder

1

DERMAVANT TAPINAROF

Psoriasis, Atopic Dermatitis

2

CERDULATINIB

Atopic Dermatitis, Vitiligo

1

DMVT-504

Primary Focal Hyperhidrosis

Preclin

LOTAMILAST

Atopic Dermatitis

Preclin

DMVT-503

Acne Vulgaris

Preclin

IMMUNOVANT RVT-1401

Autoimmune Disorders

1

ALTAVANT RVT-1201

Pulmonary Arterial Hypertension

1

RESPIVANT RVT-1601

IPF with Chronic Cough

2

ARUVANT RVT-1801

Sickle Cell Disease and β-Thalassemia

2

SINOVANT LEFAMULIN

Community-Acquired Bacterial Pneumonia

3

DERAZANTINIB

Intrahepatic Cholangiocarcinoma

3

NARONAPRIDE

IBS-C

2

BB3

Delayed Graft Function

3

Acute Kidney Injury

2

GENEVANT 5 mRNA Programs

Rare Diseases

Preclin

Additional pan-RNA Programs

Genetic Disorders

Preclin

Arbutus ARB-1467

Hepatitis B

2

AB-506

Hepatitis B

1

AB-452

Hepatitis B

Preclin

AB-729

Hepatitis B

Preclin

OTHER TONABACASE

Bacteremia

2

RVT-701

Autism

2

RVT-702

Undisclosed

Preclin

OUR PEOPLE

Leadership

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.

Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciences investing.

Members of our Public Stakeholder Advisory Group (PSAG) provide ongoing advice on how Roivant can play a role in improving the healthcare system.

WHO WE WORK WITH

Partners

We build our Vants through partnerships with companies and academic institutions that share our commitment to developing new medicines for patients and delivering innovation in healthcare. Select partners are listed below.

STAY INFORMED

News

GET IN TOUCH

Contact Us

Basel, Switzerland
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
New York, NY
Roivant Sciences, Inc.
320 West 37th Street
6th Floor
New York, NY 10018
United States
Durham, NC
Roivant Sciences, Inc.
324 Blackwell Street
Bay 12, Suite 1220
Durham, NC 27701
United States
San Francisco, CA
Myovant Sciences, Inc.
2000 Sierra Point Parkway
9th Floor
Brisbane, CA 94005
United States
Cambridge, MA
Roivant Sciences, Inc.
55 Cambridge Parkway
Suite 900E
Cambridge, MA 02142
United States
Irvine, CA
Urovant Sciences, Inc.
5151 California Avenue
Suite 250
Irvine, CA 92617
United States
Phoenix, AZ
Dermavant Sciences, Inc.
2398 East Camelback Road
Suite 1060
Phoenix, AZ 85016
United States
Warminster, PA
Arbutus Biopharma Inc.
701 Veterans Circle
Warminster, PA 18974
United States
Vancouver, BC
Genevant Sciences Corporation
8900 Glenlyon Parkway
Burnaby, British Columbia V5J 5J8
Canada
Beijing, China
Sinovant Sciences
77 Jianguo Road
Beijing, Chaoyang District
China